Preventing depressive relapse/recurrence in NHS settings through mindfulness-based cognitive therapy (MBCT)

Conditions

Recurrent depression Mental and Behavioural Disorders Depressive episode

Jesús Montero‐Marín, Verena Hinze, Shannon Maloney, Anne Maj van der Velden, Rachel Hayes et al. (9 authors)

The British Journal of Psychiatry2024-11-081 citations

10.1192/bjp.2024.178

Recovery from recurrent depression with mindfulness-based cognitive therapy and antidepressants: a qualitative study with illustrative case studies

Alice Tickell, Richard Byng, Catherine Crane, Felix Gradinger, Rachel Hayes et al. (10 authors)

BMJ Open2020-02-0121 citations

10.1136/bmjopen-2019-033892

The effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse/recurrence: results of a randomised controlled trial (the PREVENT study).

Kuyken W, Hayes R, Barrett B, Byng R, Dalgleish T, Kessler D, Lewis G, Watkins E, Morant N, Taylor RS, Byford S.

2015-09-0137 citations

10.3310/hta19730

Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial.

Kuyken W, Hayes R, Barrett B, Byng R, Dalgleish T, Kessler D, Lewis G, Watkins E, Brejcha C, Cardy J, Causley A, Cowderoy S, Evans A, Gradinger F, Kaur S, Lanham P, Morant N, Richards J, Shah P, Sutton H, Vicary R, Weaver A, Wilks J, Williams M, Taylor RS, Byford S.

2015-04-20269 citations

10.1016/s0140-6736(14)62222-4

Update to the study protocol for a randomized controlled trial comparing mindfulness-based cognitive therapy with maintenance anti-depressant treatment depressive relapse/recurrence: the PREVENT trial.

Kuyken W, Byford S, Byng R, Dalgleish T, Lewis G, Taylor R, Watkins ER, Hayes R, Lanham P, Kessler D, Morant N, Evans A.

2014-06-109 citations

10.1186/1745-6215-15-217

Study protocol for a randomized controlled trial comparing mindfulness-based cognitive therapy with maintenance anti-depressant treatment in the prevention of depressive relapse/recurrence: the PREVENT trial.

Kuyken W, Byford S, Byng R, Dalgleish T, Lewis G, Taylor R, Watkins ER, Hayes R, Lanham P, Kessler D, Morant N, Evans A.

2010-10-2027 citations

10.1186/1745-6215-11-99

Interventions

Mindfulness-based Cognitive Therapy (MBCT, see http://www.mbct.co.uk). MBCT is an 8-week, group based programme (8-15 patients per group) designed to teach people skills that prevent depressive relaps

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. A diagnosis of recurrent major depressive disorder in full or partial remission according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), with 3 or more previous major depressive episodes 2. Both males and females, aged 18 or older 3. Patients on a therapeutic dose of ADM in line with the British National Formulary (BNF) and the National Institute for Health and Clinical Excellence (NICE) guidance

Exclusion criteria

Exclusion criteria: 1. Co-morbid diagnoses of current substance dependence 2. Organic brain damage 3. Current/past psychosis, including bipolar disorder 4. Persistent anti-social behaviour 5. Persistent self-injury requiring clinical management/therapy 6. Formal concurrent psychotherapy

Design outcomes

Primary

Measure	Time frame
To determine whether MBCT is superior to maintenance antidepressant medication (m-ADM) in preventing depression relapse/recurrence over 24 months for patients with a history of recurrent depression.	—

Secondary

Measure	Time frame
A unique aspect of our trial is the inclusion of a range of secondary outcome measures including those highly valued by patients themselves. We will be comparing the following: 1. Number of depression free days 2. Residual depressive symptoms 3. Anti-depressant usage 4. Psychiatric co-morbidity 5. Quality of life, assessed by Euroqol EQ-5D 6. Cost effectiveness A further secondary objective is to determine whether an increase in mindfulness skills is the key mechanism of change. All outcome measures will be taken at 3, 6, 12, 18 and 24 months post baseline.	—

Measure

Time frame

A unique aspect of our trial is the inclusion of a range of secondary outcome measures including those highly valued by patients themselves. We will be comparing the following: 1. Number of depression free days 2. Residual depressive symptoms 3. Anti-depressant usage 4. Psychiatric co-morbidity 5. Quality of life, assessed by Euroqol EQ-5D 6. Cost effectiveness A further secondary objective is to determine whether an increase in mindfulness skills is the key mechanism of change. All outcome measures will be taken at 3, 6, 12, 18 and 24 months post baseline.

—

Countries

England, United Kingdom

Outcome results

None listed